APC Microbiome Ireland, University College Cork, Cork, Ireland.
Department of Psychiatry and Neurobehavioural Science, University College Cork, Cork, Ireland.
Curr Top Behav Neurosci. 2024;66:175-216. doi: 10.1007/7854_2023_449.
In the treatment of depressive disorders, conventional antidepressant therapy has been the mainstay of clinical management, along with well-established nonpharmacological interventions such as various kinds of psychotherapy. Over the last 2 decades, there has been considerable interest in the role of the gastrointestinal system and its microbiota on brain function, behavior, and mental health. Components of what is referred to as the microbiota-gut-brain axis have been uncovered, and further research has elicited functional capabilities such as "gut-brain modules." Some studies have found associations with compositional alterations of gut microbiota in patients with depressive disorders and individuals experiencing symptoms of depression. Regarding the pathogenesis and neurobiology of depression itself, there appears to be a multifactorial contribution, in addition to the theories involving deficits in catecholaminergic and monoamine neurotransmission. Interestingly, there is evidence to suggest that antidepressants may play a role in modulating the gut microbiota, thereby possibly having an impact on the microbiota-gut-brain axis in this manner. The development of prebiotics, probiotics, and synbiotics has led to studies investigating not only their impact on the microbiota but also their therapeutic value in mental health. These psychobiotics have the potential to be used as therapeutic adjuncts in the treatment of depression. Regarding future directions, and in an attempt to further understand the role of the microbiota-gut-brain axis in depression, more studies such as those involving fecal microbiota transplantation will be required. In addition to recent findings, it is also suggested that more research will have to be undertaken to elicit whether specific strains of gut organisms are linked to depression. In terms of further investigation of the therapeutic potential of prebiotics, probiotics, and synbiotics as adjuncts to antidepressant treatment, we also expect there to be more research targeting specific microorganisms, as well as a strong focus on the effects of specific prebiotic fibers from an individualized (personalized) point of view.
在治疗抑郁症方面,传统的抗抑郁药物治疗一直是临床管理的主要方法,同时还有各种心理治疗等经过验证的非药物干预方法。在过去的 20 年中,人们对胃肠道系统及其微生物群对大脑功能、行为和心理健康的作用产生了浓厚的兴趣。人们已经发现了所谓的微生物群-肠道-大脑轴的组成部分,并且进一步的研究还揭示了“肠道-大脑模块”等功能能力。一些研究发现,抑郁症患者和出现抑郁症状的个体的肠道微生物群组成发生改变。关于抑郁症本身的发病机制和神经生物学,除了涉及儿茶酚胺能和单胺能神经递质缺失的理论外,似乎还有多种因素的共同作用。有趣的是,有证据表明抗抑郁药可能在调节肠道微生物群方面发挥作用,从而可能以这种方式对微生物群-肠道-大脑轴产生影响。益生元、益生菌和合生菌的发展导致了研究不仅关注它们对微生物群的影响,还关注它们在心理健康方面的治疗价值。这些心理益生菌有可能被用作治疗抑郁症的辅助治疗方法。关于未来的方向,为了进一步了解微生物群-肠道-大脑轴在抑郁症中的作用,需要进行更多的研究,如涉及粪便微生物群移植的研究。除了最近的发现,还需要进行更多的研究,以确定肠道生物是否与抑郁症有关。在进一步研究益生元、益生菌和合生菌作为抗抑郁治疗的辅助治疗的治疗潜力方面,我们还预计将有更多的研究针对特定的微生物,并且还将从个体化的角度(个性化)强烈关注特定的益生元纤维的作用。
Curr Top Behav Neurosci. 2024
Prog Neuropsychopharmacol Biol Psychiatry. 2021-3-2
Molecules. 2023-4-4
Prog Neuropsychopharmacol Biol Psychiatry. 2024-8-30
Prog Neuropsychopharmacol Biol Psychiatry. 2021-3-2
Eur J Pharmacol. 2022-9-15
Curr Neuropharmacol. 2025
J Psychopharmacol. 2023-3
Nat Commun. 2022-12-6
Nat Commun. 2022-12-6
Cell Host Microbe. 2022-6-8
Front Cell Infect Microbiol. 2022